Indication
Pseudohypoparathyroidism Type 1a
2 clinical trials
1 product
1 drug
Clinical trial
Open-Label Extension Study of Theophylline for Treatment of PseudohypoparathyroidismStatus: , Estimated PCD: 2026-06-30
Product
TheophyllineClinical trial
Phase 2 Study of Theophylline Treatment for PseudohypoparathyroidismStatus: Recruiting, Estimated PCD: 2026-06-30
Drug
Varlilumab